JAK Safety -- The Lowdown on Infection: Drs. Kevin Winthrop and Jonathan Kay Infections in ORAL Surveillance: Drs. Kevin Winthrop and Jonathan Kay Infliximab Drug Monitoring in PsA, RA, AxSpA: Dr. Pedro Castillo Lupus and Pregnancy: Dr. Sheila Reyes Secukinumab Effect on CV Risks in PsA, axSpA: Dr. Sheila Reyes
Glucocorticoids and CV risk in RA: Drs. Aurelie Najm and Jon Giles Might Tofacitinib Reduce Malignancy Risk with Patients with RA? Dr. Jonathan Kay Rheumatic Diseases Can Take your Breath Away: Dr.Janet Pope Best of PsA Day 4 (Tuesday): MACE in PsA: Dr. Rachel Tate Predicting Progression from Psoriasis to PsA: Dr. Robert Chao David Liew Interview Dr. Seoyoung Kim About Tofacitinib and Malignancy Risk. Third Time's the Charm - COVID Vaccination While on Rituximab: Dr. Yuz Yusof Can We Stop...
Dr. Michelle Petri - Urine Proteome Advances: What Do They Mean? "Doctor, I Can Tell When It's Raining!" - Dr. Aurelie Najm NSAIDS Prevent Heart Attacks in PsA: Dr. Richard Conway Pediatric Psoriatic Arthritis: Dr. Eric Ruderman irAEs: Drs. Cassie Calabrese and David Liew TNFi in axSpA: Dr. Swetha Alexander
Sex, Age and Race/Ethnic Differences in Multimorbidity in Lupus: Drs. Duarte and Mehta Hospitalization Trends in Patients with Psoriatic Arthritis: Dr. Olga Petryna Patient Reported Outcomes in axSpA: Dr. Swetha Alexander Pregnancy Outcomes in PsA, SpA, RA: Dr. Rachel Tate Guselkemab vs. Ustekinumab in PsA: Dr. Richard Conway Medication Preferences in Patients with Psoriatic Arthritis: Dr. Olga Petryna Dr. Michelle Petri - Urine Proteome Advances: What Do They Mean?